Litcius/Paper detail

Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer

Shu‐Fen Chiang, Kevin Chih‐Yang Huang, William Tzu‐Liang Chen, Tsung-Wei Chen, Tao‐Wei Ke, K. S. Clifford Chao

2021Cancer Immunology Immunotherapy16 citationsDOIOpen Access PDF

Topics & Concepts

ChemoradiotherapyMedicineColorectal cancerOncologyInternal medicineHazard ratioImmunosurveillanceCytotoxic T cellCD8Radiation therapyCancer researchImmunologyImmune systemCancerBiologyConfidence intervalBiochemistryIn vitroS100 Proteins and AnnexinsColorectal Cancer Surgical TreatmentsColorectal and Anal Carcinomas
Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer | Litcius